St. Jude Eyes Possible Acquisition Of Heart Failure Monitor Firm CardioMEMS
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical is placing a $60 million bet on wireless implantable heart failure monitor developer CardioMEMS and has acquired an exclusive option to own the entire company via a Sept. 7 agreement
You may also be interested in...
St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity
With the publication of the CHAMPION clinical trial results, CardioMEMS and its suitor St. Jude Medical took another step toward leading the pack in what they say is a multi-billion dollar market opportunity in hemodynamic heart failure monitoring.
St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity
With the publication of the CHAMPION clinical trial results, CardioMEMS and its suitor St. Jude Medical took another step toward leading the pack in what they say is a multi-billion dollar market opportunity in hemodynamic heart failure monitoring.
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010
Medical device financings during the third quarter of 2010 brought in $997 million, an increase of 82% from the second quarter's $548 million. While Q3 M&A activity was down slightly from last quarter - only 15 mergers were completed, compared with 18 in Q2 - more money was involved: an impressive $6.7 billion. The venture rounds for PacBio and Complete Genomics boosted late-stage VC money to $171 million in the third quarter, two-thirds of the entire amount for the in vitro diagnostics/research industry. Despite only five acquisitions closing during the third quarter, the M&A dollar volume for the IVD/research industry was just north of $2 billion.